ROIV:NASDAQ
Roivant Sciences Ltd
$39.57
arrow_upward
+0.18%(+0.070) 1D
$39.90
arrow_upward
+0.83% (+0.33)todayPre-market
Closed: Sep 16, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ROIV...
Open
$39.77
High
$40.44
Low
$39.16
Mkt. cap
28.58B
Avg. vol.
8.09M
Volume
439.00
52-wk high
$42.50
52-wk low
$14.50
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
Open
$39.77
High
$40.44
Low
$39.16
Mkt. cap
28.58B
Avg. vol.
8.09M
Volume
439.00
52-wk high
$42.50
52-wk low
$14.50
EPS
-$0.39
Beta
1.12
Shares outstanding
722.32M
No. of employees
721
News stories
From web sources and news partners
Investing.com
·
12 hours ago
Stifel initiates Roivant Sciences stock with buy rating, $51 target
StreetInsider
·
13 hours ago
Stifel Starts Roivant Sciences (ROIV) at Buy
Profile
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel. Wikipedia
About Roivant Sciences Ltd